title: Ochratoxin A: 13-week oral toxicity and cell proliferation in male F344/n rats.
abstract: Ochratoxin A (OTA) is nephrotoxic and a potent renal carcinogen. Male rats are most susceptible to OTA toxicity, and chronic administration of OTA (70 and 210 microg/kg bw) for 2 years has been shown to induce high incidences of adenomas and carcinomas arising from the straight segment of the proximal tubule epithelium. In contrast, treatment with a lower dose of 21 microg/kg bw did not result in increased tumor rates, suggesting a nonlinear dose response for renal tumor formation by OTA. Since the mechanism of OTA carcinogenicity is still largely unknown, this study was conducted to investigate early functional and pathological effects of OTA and to determine if sustained stimulation of renal cell proliferation plays a role. Male F344/N rats were treated with OTA for up to 13 weeks under conditions of the National Toxicology Program (NTP) bioassay. Cell proliferation in the renal cortex and outer stripe of the outer medulla (OSOM) was determined using bromodeoxyuridine incorporation and immunohistochemistry. Histopathological examination showed renal alterations in mid- and high-dose-treated animals involving single-cell death and prominent nuclear enlargement within the straight proximal tubules. Treatment with OTA at doses of 70 and 210 microg/kg bw led to a marked dose- and time-dependent increase in renal cell proliferation, extending from the medullary rays into the OSOM. No effects were evident in kidneys of low-dose-treated animals or in the liver, which is not a target for OTA carcinogenicity. A no observed effect level in this study was established at 21 microg/kg bw, correlating with the dose in the NTP 2-year bioassay that did not produce renal tumors. The apparent correlation between enhanced cell turnover and tumor formation induced by OTA indicates that stimulation of cell proliferation may play an important role in OTA carcinogenicity and provides further evidence for an epigenetic, thresholded mechanism.
authors.affiliation: Department of Toxicology, University of Würzburg, Würzburg, Germany.
authors.forename: Eva
authors.initials: E
authors.lastname: Rached
authors.forename: Gordon C
authors.initials: GC
authors.lastname: Hard
authors.forename: Kai
authors.initials: K
authors.lastname: Blumbach
authors.forename: Klaus
authors.initials: K
authors.lastname: Weber
authors.forename: Regina
authors.initials: R
authors.lastname: Draheim
authors.forename: Werner K
authors.initials: WK
authors.lastname: Lutz
authors.forename: Sibel
authors.initials: S
authors.lastname: Ozden
authors.forename: Ulrich
authors.initials: U
authors.lastname: Steger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Dekant
authors.forename: Angela
authors.initials: A
authors.lastname: Mally
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000963:Antimetabolites; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D001973:Bromodeoxyuridine; D002273:Carcinogens / Q000493:pharmacokinetics / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000378:metabolism; D008297:Male; D009793:Ochratoxins / Q000493:pharmacokinetics / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D014018:Tissue Distribution
chemical_list: D000963:Antimetabolites; D002273:Carcinogens; D009793:Ochratoxins; C025589:ochratoxin A; D001973:Bromodeoxyuridine